-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Early Detection & Screening
-
Risk Prediction Model Demonstrates Superior Performance vs. NELSON Criteria for Identifying Individuals for Screening
Dr. Jens Vogel-Claussen says the PLCOm2012 model, which includes family history and other factors, detected 97% of lung cancer cases compared to a 77% detection rate with NELSON criteria.
-
Multifaceted Approach Needed for Early Lung Cancer Detection
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap.
-
New Screening Approach Needed to Detect Lung Cancer in Patients who Never Smoked
During ACLC 2022, Dr. Gee-Chen Chang made the case for moving beyond smoking history to identify at-risk patients and shared an alternative risk predication model that compared favorably against NLST and NELSON.
-
Opinion: Updated Screening Guidance Needs More Commitment, Action Steps
Prof. Denis Horgan, executive director for the European Alliance for Personalised Medicine, writes that while the intentions behind the EU’s new cancer screening recommendations are laudable, they lack a roadmap for turning ideas into reality.
-
Comparable Efficacy, Disruptive Price for an Alternative EGFR TKI?
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval.
-
Lung Cancer Risk Prediction Model Demonstrates Readiness for Clinical Application
Evidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening.
-
IASLC Releases Position Statement on Air Pollution on Earth Day
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer.
-
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT.
-
Role of Liquid Biopsy in the Clinic Growing
Lung cancer specialists are slowly being faced with the challenge of how to balance the benefits of next-generation tumor tissue testing against those of liquid biopsy in the clinic. During the 2021 International Society of Liquid Biopsy (ISLB) Congress, Natasha Leighl, MD, of Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, provided attendees with…
-
Association of Race with Lung Cancer Risk Among Adults Undergoing Lung Cancer Screening
Data suggest lung cancer risk scores are not aligned with lung cancer diagnoses in Black patients. Take a closer look at how race influences lung cancer screening.